Literature DB >> 27009094

HIV-1 Latency and Eradication: Past, Present and Future.

Prasun K Datta, Rafal Kaminski, Wenhui Hu, Vanessa Pirrone, Neil T Sullivan, Michael R Nonnemacher, Will Dampier, Brian Wigdahl, Kamel Khalili1.   

Abstract

BACKGROUND: It is well established that antiretroviral therapy (ART), while highly effective in controlling HIV replication, cannot eliminate virus from the body. Therefore, the majority of HIV-1-infected individuals remain at risk for developing AIDS due to persistence of infected reservoir cells serving as a source of virus re-emergence. Several reservoirs containing replication competent HIV-1 have been identified, most notably CD4+ T cells. Cells of the myeloid lineage, which are the first line of defense against pathogens and participate in HIV dissemination into sanctuary organs, also serve as cellular reservoirs of HIV-1. In latently infected resting CD4+ T cells, the integrated copies of proviral DNA remain in a dormant state, yet possess the ability to produce replication competent virus after cellular activation. Studies have demonstrated that modification of chromatin structure plays a role in establishing persistence, in part suggesting that latency is, controlled epigenetically.
CONCLUSION: Current efforts to eradicate HIV-1 from this cell population focus primarily on a "shock and kill" approach through cellular reactivation to trigger elimination of virus producing cells by cytolysis or host immune responses. However, studies revealed several limitations to this approach that require more investigation to assess its clinical application. Recent advances in gene editing technology prompted use of this approach for inactivating integrated proviral DNA in the genome of latently infected cells. This technology, which requires a detailed understanding of the viral genetics and robust delivery, may serve as a powerful strategy to eliminate the latent reservoir in the host leading to a sterile cure of AIDS.

Entities:  

Mesh:

Year:  2016        PMID: 27009094      PMCID: PMC5157928          DOI: 10.2174/1570162x14666160324125536

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  150 in total

1.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

2.  Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery.

Authors:  Huanyu Dou; Christopher J Destache; Justin R Morehead; R Lee Mosley; Michael D Boska; Jeffrey Kingsley; Santhi Gorantla; Larisa Poluektova; Jay A Nelson; Mahesh Chaubal; Jane Werling; James Kipp; Barrett E Rabinow; Howard E Gendelman
Journal:  Blood       Date:  2006-06-29       Impact factor: 22.113

3.  Distribution of brain HIV load in AIDS.

Authors:  C A Wiley; V Soontornniyomkij; L Radhakrishnan; E Masliah; J Mellors; S A Hermann; P Dailey; C L Achim
Journal:  Brain Pathol       Date:  1998-04       Impact factor: 6.508

4.  Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.

Authors:  M C Strain; S Letendre; S K Pillai; T Russell; C C Ignacio; H F Günthard; B Good; D M Smith; S M Wolinsky; M Furtado; J Marquie-Beck; J Durelle; I Grant; D D Richman; T Marcotte; J A McCutchan; R J Ellis; J K Wong
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.

Authors:  M Göttlicher; S Minucci; P Zhu; O H Krämer; A Schimpf; S Giavara; J P Sleeman; F Lo Coco; C Nervi; P G Pelicci; T Heinzel
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

6.  Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype.

Authors:  Deirdre D Scripture-Adams; David G Brooks; Yael D Korin; Jerome A Zack
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 7.  A simian immunodeficiency virus macaque model of highly active antiretroviral treatment: viral latency in the periphery and the central nervous system.

Authors:  Janice E Clements; Lucio Gama; David R Graham; Joseph L Mankowski; M C Zink
Journal:  Curr Opin HIV AIDS       Date:  2011-01       Impact factor: 4.283

8.  Humanized Rag2(-/-)gammac(-/-) (RAG-hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year.

Authors:  Bradford K Berges; Sarah R Akkina; Leila Remling; Ramesh Akkina
Journal:  Virology       Date:  2009-11-18       Impact factor: 3.616

9.  Generation of HIV latency in humanized BLT mice.

Authors:  Paul W Denton; Rikke Olesen; Shailesh K Choudhary; Nancy M Archin; Angela Wahl; Michael D Swanson; Morgan Chateau; Tomonori Nochi; John F Krisko; Rae Ann Spagnuolo; David M Margolis; J Victor Garcia
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

10.  Proviral HIV-genome-wide and pol-gene specific zinc finger nucleases: usability for targeted HIV gene therapy.

Authors:  Misaki Wayengera
Journal:  Theor Biol Med Model       Date:  2011-07-22       Impact factor: 2.432

View more
  17 in total

Review 1.  Novel AIDS therapies based on gene editing.

Authors:  Kamel Khalili; Martyn K White; Jeffrey M Jacobson
Journal:  Cell Mol Life Sci       Date:  2017-02-16       Impact factor: 9.261

2.  Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1+ and TIGIT+ CD4 T Cells.

Authors:  George N Llewellyn; Eduardo Seclén; Stephen Wietgrefe; Siyu Liu; Morgan Chateau; Hua Pei; Katherine Perkey; Matthew D Marsden; Sarah J Hinkley; David E Paschon; Michael C Holmes; Jerome A Zack; Stan G Louie; Ashley T Haase; Paula M Cannon
Journal:  J Virol       Date:  2019-05-01       Impact factor: 5.103

3.  Computational Analysis Concerning the Impact of DNA Accessibility on CRISPR-Cas9 Cleavage Efficiency.

Authors:  Cheng-Han Chung; Alexander G Allen; Neil T Sullivan; Andrew Atkins; Michael R Nonnemacher; Brian Wigdahl; Will Dampier
Journal:  Mol Ther       Date:  2019-10-15       Impact factor: 11.454

Review 4.  A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System.

Authors:  Anna Bellizzi; Nicholas Ahye; Gauthami Jalagadugula; Hassen S Wollebo
Journal:  J Neuroimmune Pharmacol       Date:  2019-09-11       Impact factor: 4.147

5.  Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging.

Authors:  Bhavesh D Kevadiya; Aditya N Bade; Christopher Woldstad; Benson J Edagwa; JoEllyn M McMillan; Balasrinivasa R Sajja; Michael D Boska; Howard E Gendelman
Journal:  Acta Biomater       Date:  2016-12-01       Impact factor: 8.947

6.  Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics.

Authors:  Will Dampier; Neil T Sullivan; Joshua Chang Mell; Vanessa Pirrone; Garth D Ehrlich; Cheng-Han Chung; Alexander G Allen; Mathew DeSimone; Wen Zhong; Katherine Kercher; Shendra Passic; Jean W Williams; Zsofia Szep; Kamel Khalili; Jeffrey M Jacobson; Michael R Nonnemacher; Brian Wigdahl
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-27       Impact factor: 2.205

Review 7.  lncRNAs in T lymphocytes: RNA regulation at the heart of the immune response.

Authors:  Leah M Plasek; Saba Valadkhan
Journal:  Am J Physiol Cell Physiol       Date:  2020-12-09       Impact factor: 4.249

8.  Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui.

Authors:  Pengfei Wang; Panpan Lu; Xiying Qu; Yinzhong Shen; Hanxian Zeng; Xiaoli Zhu; Yuqi Zhu; Xian Li; Hao Wu; Jianqing Xu; Hongzhou Lu; Zhongjun Ma; Huanzhang Zhu
Journal:  Sci Rep       Date:  2017-08-25       Impact factor: 4.379

9.  Specific Destruction of HIV Proviral p17 Gene in T Lymphoid Cells Achieved by the Genome Editing Technology.

Authors:  Tsunao Kishida; Akika Ejima; Osam Mazda
Journal:  Front Microbiol       Date:  2016-06-28       Impact factor: 5.640

Review 10.  The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook.

Authors:  Hager Mohamed; Vandana Miller; Stephen R Jennings; Brian Wigdahl; Fred C Krebs
Journal:  J Immunol Res       Date:  2020-05-25       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.